AZN AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About AstraZeneca (NYSE: AZN)
›
AstraZeneca (NYSE: AZN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 96,100 employees.
The shares were at 184.45 USD on 13 November 2026, up 6.3% over 52 weeks. Its 52-week range is 153.41 USD to 212.71 USD: the price is 13.3% below the high and 20.2% above the low.
At a market capitalisation of 286.07B USD, it trades at 26.1 times trailing earnings and 16.3 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 26.6, so AZN is valued in line with them. It pays a dividend yielding 1.74% (it pays out 45% of its earnings), against a median of 2.76% among the dividend payers in that peer group.
AstraZeneca reports return on equity of 21.0%, an operating margin of 25.8% and revenue up 6.7% year over year.
Its debt exceeds its cash by 26.16B USD, a debt-to-equity ratio of 0.60. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 208.07 USD is 12.8% above the current price. The next earnings report is expected on 9 February 2027.